New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study
The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the...
Ausführliche Beschreibung
Autor*in: |
Lu, Xiangyu [verfasserIn] Liu, Dingyi [verfasserIn] Zou, Yajun [verfasserIn] Yang, Jialiang [verfasserIn] Wu, Liji [verfasserIn] Zhang, Xiaoyu [verfasserIn] Zhao, Gang [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2024 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
Enthalten in: Journal of organometallic chemistry - New York, NY [u.a.] : Elsevier, 1963, 1006 |
---|---|
Übergeordnetes Werk: |
volume:1006 |
DOI / URN: |
10.1016/j.jorganchem.2024.123022 |
---|
Katalog-ID: |
ELV066756987 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | ELV066756987 | ||
003 | DE-627 | ||
005 | 20240127093320.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240127s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jorganchem.2024.123022 |2 doi | |
035 | |a (DE-627)ELV066756987 | ||
035 | |a (ELSEVIER)S0022-328X(24)00018-4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
082 | 0 | 4 | |a 540 |q VZ |
084 | |a 35.00 |2 bkl | ||
100 | 1 | |a Lu, Xiangyu |e verfasserin |4 aut | |
245 | 1 | 0 | |a New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study |
264 | 1 | |c 2024 | |
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. | ||
650 | 4 | |a Ferrocene | |
650 | 4 | |a Cyclopalladated compound | |
650 | 4 | |a Single crystal | |
650 | 4 | |a Anticancer activity | |
700 | 1 | |a Liu, Dingyi |e verfasserin |4 aut | |
700 | 1 | |a Zou, Yajun |e verfasserin |4 aut | |
700 | 1 | |a Yang, Jialiang |e verfasserin |4 aut | |
700 | 1 | |a Wu, Liji |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Xiaoyu |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Gang |e verfasserin |0 (orcid)0000-0002-7272-3270 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of organometallic chemistry |d New York, NY [u.a.] : Elsevier, 1963 |g 1006 |h Online-Ressource |w (DE-627)302469990 |w (DE-600)1491530-3 |w (DE-576)094950318 |x 1872-8561 |7 nnns |
773 | 1 | 8 | |g volume:1006 |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2050 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2056 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2122 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
936 | b | k | |a 35.00 |j Chemie: Allgemeines |q VZ |
951 | |a AR | ||
952 | |d 1006 |
author_variant |
x l xl d l dl y z yz j y jy l w lw x z xz g z gz |
---|---|
matchkey_str |
article:18728561:2024----::efroeeylplaaecmonsyteixasnlcytltutradni |
hierarchy_sort_str |
2024 |
bklnumber |
35.00 |
publishDate |
2024 |
allfields |
10.1016/j.jorganchem.2024.123022 doi (DE-627)ELV066756987 (ELSEVIER)S0022-328X(24)00018-4 DE-627 ger DE-627 rda eng 540 VZ 35.00 bkl Lu, Xiangyu verfasserin aut New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study 2024 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. Ferrocene Cyclopalladated compound Single crystal Anticancer activity Liu, Dingyi verfasserin aut Zou, Yajun verfasserin aut Yang, Jialiang verfasserin aut Wu, Liji verfasserin aut Zhang, Xiaoyu verfasserin aut Zhao, Gang verfasserin (orcid)0000-0002-7272-3270 aut Enthalten in Journal of organometallic chemistry New York, NY [u.a.] : Elsevier, 1963 1006 Online-Ressource (DE-627)302469990 (DE-600)1491530-3 (DE-576)094950318 1872-8561 nnns volume:1006 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.00 Chemie: Allgemeines VZ AR 1006 |
spelling |
10.1016/j.jorganchem.2024.123022 doi (DE-627)ELV066756987 (ELSEVIER)S0022-328X(24)00018-4 DE-627 ger DE-627 rda eng 540 VZ 35.00 bkl Lu, Xiangyu verfasserin aut New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study 2024 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. Ferrocene Cyclopalladated compound Single crystal Anticancer activity Liu, Dingyi verfasserin aut Zou, Yajun verfasserin aut Yang, Jialiang verfasserin aut Wu, Liji verfasserin aut Zhang, Xiaoyu verfasserin aut Zhao, Gang verfasserin (orcid)0000-0002-7272-3270 aut Enthalten in Journal of organometallic chemistry New York, NY [u.a.] : Elsevier, 1963 1006 Online-Ressource (DE-627)302469990 (DE-600)1491530-3 (DE-576)094950318 1872-8561 nnns volume:1006 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.00 Chemie: Allgemeines VZ AR 1006 |
allfields_unstemmed |
10.1016/j.jorganchem.2024.123022 doi (DE-627)ELV066756987 (ELSEVIER)S0022-328X(24)00018-4 DE-627 ger DE-627 rda eng 540 VZ 35.00 bkl Lu, Xiangyu verfasserin aut New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study 2024 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. Ferrocene Cyclopalladated compound Single crystal Anticancer activity Liu, Dingyi verfasserin aut Zou, Yajun verfasserin aut Yang, Jialiang verfasserin aut Wu, Liji verfasserin aut Zhang, Xiaoyu verfasserin aut Zhao, Gang verfasserin (orcid)0000-0002-7272-3270 aut Enthalten in Journal of organometallic chemistry New York, NY [u.a.] : Elsevier, 1963 1006 Online-Ressource (DE-627)302469990 (DE-600)1491530-3 (DE-576)094950318 1872-8561 nnns volume:1006 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.00 Chemie: Allgemeines VZ AR 1006 |
allfieldsGer |
10.1016/j.jorganchem.2024.123022 doi (DE-627)ELV066756987 (ELSEVIER)S0022-328X(24)00018-4 DE-627 ger DE-627 rda eng 540 VZ 35.00 bkl Lu, Xiangyu verfasserin aut New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study 2024 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. Ferrocene Cyclopalladated compound Single crystal Anticancer activity Liu, Dingyi verfasserin aut Zou, Yajun verfasserin aut Yang, Jialiang verfasserin aut Wu, Liji verfasserin aut Zhang, Xiaoyu verfasserin aut Zhao, Gang verfasserin (orcid)0000-0002-7272-3270 aut Enthalten in Journal of organometallic chemistry New York, NY [u.a.] : Elsevier, 1963 1006 Online-Ressource (DE-627)302469990 (DE-600)1491530-3 (DE-576)094950318 1872-8561 nnns volume:1006 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.00 Chemie: Allgemeines VZ AR 1006 |
allfieldsSound |
10.1016/j.jorganchem.2024.123022 doi (DE-627)ELV066756987 (ELSEVIER)S0022-328X(24)00018-4 DE-627 ger DE-627 rda eng 540 VZ 35.00 bkl Lu, Xiangyu verfasserin aut New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study 2024 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. Ferrocene Cyclopalladated compound Single crystal Anticancer activity Liu, Dingyi verfasserin aut Zou, Yajun verfasserin aut Yang, Jialiang verfasserin aut Wu, Liji verfasserin aut Zhang, Xiaoyu verfasserin aut Zhao, Gang verfasserin (orcid)0000-0002-7272-3270 aut Enthalten in Journal of organometallic chemistry New York, NY [u.a.] : Elsevier, 1963 1006 Online-Ressource (DE-627)302469990 (DE-600)1491530-3 (DE-576)094950318 1872-8561 nnns volume:1006 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 35.00 Chemie: Allgemeines VZ AR 1006 |
language |
English |
source |
Enthalten in Journal of organometallic chemistry 1006 volume:1006 |
sourceStr |
Enthalten in Journal of organometallic chemistry 1006 volume:1006 |
format_phy_str_mv |
Article |
bklname |
Chemie: Allgemeines |
institution |
findex.gbv.de |
topic_facet |
Ferrocene Cyclopalladated compound Single crystal Anticancer activity |
dewey-raw |
540 |
isfreeaccess_bool |
false |
container_title |
Journal of organometallic chemistry |
authorswithroles_txt_mv |
Lu, Xiangyu @@aut@@ Liu, Dingyi @@aut@@ Zou, Yajun @@aut@@ Yang, Jialiang @@aut@@ Wu, Liji @@aut@@ Zhang, Xiaoyu @@aut@@ Zhao, Gang @@aut@@ |
publishDateDaySort_date |
2024-01-01T00:00:00Z |
hierarchy_top_id |
302469990 |
dewey-sort |
3540 |
id |
ELV066756987 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">ELV066756987</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240127093320.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240127s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jorganchem.2024.123022</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV066756987</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0022-328X(24)00018-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lu, Xiangyu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ferrocene</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclopalladated compound</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Single crystal</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anticancer activity</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Dingyi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zou, Yajun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Jialiang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Liji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Xiaoyu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhao, Gang</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-7272-3270</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of organometallic chemistry</subfield><subfield code="d">New York, NY [u.a.] : Elsevier, 1963</subfield><subfield code="g">1006</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)302469990</subfield><subfield code="w">(DE-600)1491530-3</subfield><subfield code="w">(DE-576)094950318</subfield><subfield code="x">1872-8561</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.00</subfield><subfield code="j">Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1006</subfield></datafield></record></collection>
|
author |
Lu, Xiangyu |
spellingShingle |
Lu, Xiangyu ddc 540 bkl 35.00 misc Ferrocene misc Cyclopalladated compound misc Single crystal misc Anticancer activity New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study |
authorStr |
Lu, Xiangyu |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)302469990 |
format |
electronic Article |
dewey-ones |
540 - Chemistry & allied sciences |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1872-8561 |
topic_title |
540 VZ 35.00 bkl New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study Ferrocene Cyclopalladated compound Single crystal Anticancer activity |
topic |
ddc 540 bkl 35.00 misc Ferrocene misc Cyclopalladated compound misc Single crystal misc Anticancer activity |
topic_unstemmed |
ddc 540 bkl 35.00 misc Ferrocene misc Cyclopalladated compound misc Single crystal misc Anticancer activity |
topic_browse |
ddc 540 bkl 35.00 misc Ferrocene misc Cyclopalladated compound misc Single crystal misc Anticancer activity |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Journal of organometallic chemistry |
hierarchy_parent_id |
302469990 |
dewey-tens |
540 - Chemistry |
hierarchy_top_title |
Journal of organometallic chemistry |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)302469990 (DE-600)1491530-3 (DE-576)094950318 |
title |
New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study |
ctrlnum |
(DE-627)ELV066756987 (ELSEVIER)S0022-328X(24)00018-4 |
title_full |
New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study |
author_sort |
Lu, Xiangyu |
journal |
Journal of organometallic chemistry |
journalStr |
Journal of organometallic chemistry |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
500 - Science |
recordtype |
marc |
publishDateSort |
2024 |
contenttype_str_mv |
zzz |
author_browse |
Lu, Xiangyu Liu, Dingyi Zou, Yajun Yang, Jialiang Wu, Liji Zhang, Xiaoyu Zhao, Gang |
container_volume |
1006 |
class |
540 VZ 35.00 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Lu, Xiangyu |
doi_str_mv |
10.1016/j.jorganchem.2024.123022 |
normlink |
(ORCID)0000-0002-7272-3270 |
normlink_prefix_str_mv |
(orcid)0000-0002-7272-3270 |
dewey-full |
540 |
author2-role |
verfasserin |
title_sort |
new ferrocene cyclopalladated compounds: synthesis, x-ray single crystal structure and in vitro anticancer activity study |
title_auth |
New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study |
abstract |
The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. |
abstractGer |
The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. |
abstract_unstemmed |
The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_101 GBV_ILN_105 GBV_ILN_110 GBV_ILN_150 GBV_ILN_151 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2034 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2056 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2088 GBV_ILN_2106 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2470 GBV_ILN_2507 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 |
title_short |
New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study |
remote_bool |
true |
author2 |
Liu, Dingyi Zou, Yajun Yang, Jialiang Wu, Liji Zhang, Xiaoyu Zhao, Gang |
author2Str |
Liu, Dingyi Zou, Yajun Yang, Jialiang Wu, Liji Zhang, Xiaoyu Zhao, Gang |
ppnlink |
302469990 |
mediatype_str_mv |
c |
isOA_txt |
false |
hochschulschrift_bool |
false |
doi_str |
10.1016/j.jorganchem.2024.123022 |
up_date |
2024-07-06T18:53:12.308Z |
_version_ |
1803856896127401984 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">ELV066756987</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240127093320.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240127s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jorganchem.2024.123022</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV066756987</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0022-328X(24)00018-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lu, Xiangyu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New ferrocene cyclopalladated compounds: Synthesis, X-ray single crystal structure and in vitro anticancer activity study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The biological potential of ferrocene cyclopalladated compounds as anticancer agents has garnered significant attention. However, the limited availability of these compounds due to their sparse synthesis constrains the broader exploration of their anticancer mechanisms. In this paper, we report the synthesis and comprehensive characterization of four novel ferrocene cyclopalladated compounds (C1, C2, C3, and C4) employing ¹H, ¹³C NMR, ESI-MS, and elemental analysis techniques. The molecular structures of C1 and C3 were determined by X-ray single-crystal diffraction. Furthermore, when tested in vitro, these compounds exhibited superior inhibition of mouse melanoma cell (B16F10) proliferation compared to cisplatin. Notably, compound C2 displayed approximately 17-fold higher potency against mouse lymphoma cells (YAC-1) than cisplatin. This enhanced efficacy signifies the promising role of ferrocene cyclopalladated compounds in anticancer therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ferrocene</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclopalladated compound</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Single crystal</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anticancer activity</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Dingyi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zou, Yajun</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Jialiang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Liji</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhang, Xiaoyu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhao, Gang</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-7272-3270</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of organometallic chemistry</subfield><subfield code="d">New York, NY [u.a.] : Elsevier, 1963</subfield><subfield code="g">1006</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)302469990</subfield><subfield code="w">(DE-600)1491530-3</subfield><subfield code="w">(DE-576)094950318</subfield><subfield code="x">1872-8561</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2056</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.00</subfield><subfield code="j">Chemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1006</subfield></datafield></record></collection>
|
score |
7.3994474 |